The London and Cambridge Life Sciences and Technology team advised Novo Holdings as a lead investor in Roslin Tech’s £11 million Series A funding round. Other participating investors included Kairos Capital Group, Nutreco, Future Planet Capital, Esco Lifesciences and Alchimia. The new funding will allow Roslin Tech to expand its cell line portfolio and to further develop the protocols for scale up of its cells into cost competitive cell biomass for meat production.
Roslin Tech is a Scottish agriculture biotechnology company which is developing and commercializing novel biotechnologies for alternative protein sectors and animal health.
Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets. Novo Holdings is recognised as a leading international life science investor, with a focus on creating long-term value.
The Goodwin team was led by Sophie McGrath, Adam Thatcher and Matthew Shelley.
For additional details, please read the press release.